Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
Zapf, C.W., Bloom, J.D., McBean, J.L., Dushin, R.G., Nittoli, T., Otteng, M., Ingalls, C., Golas, J.M., Liu, H., Lucas, J., Boschelli, F., Hu, Y., Vogan, E., Levin, J.I.(2011) Bioorg Med Chem Lett 21: 3411-3416
- PubMed: 21515049 
- DOI: 10.1016/j.bmcl.2011.03.112
- Primary Citation of Related Structures:  
3R91 - PubMed Abstract: 
A novel series of macrocyclic ortho-aminobenzamide Hsp90 inhibitors is reported. In continuation of our research in this area, macrocyclic amides and lactams were explored to reduce the risk of hERG liabilities. This effort culminated in the discovery of ...